Asiatic Acid Attenuates Infarct Volume, Mitochondrial Dysfunction, and Matrix Metalloproteinase-9 Induction After Focal Cerebral Ischemia
Open Access
- 1 June 2012
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Stroke
- Vol. 43 (6), 1632-1638
- https://doi.org/10.1161/STROKEAHA.111.639427
Abstract
Background and Purpose— Asiatic acid (AA) has been shown to attenuate cerebral infarction in a mouse model of focal ischemia and shows promise as a neuroprotective stroke therapy. To facilitate translation of these findings to clinical studies, we determined pharmacokinetics, a dose–response relationship, the therapeutic time window, and efficacy using multiple stroke models. We also explored potential mechanisms of action. Methods— Escalating doses of intravenous AA were administered and serum concentrations were measured at multiple time points for the pharmacokinetic studies. Subsequently, a dose–response relationship was determined followed by administration at different intervals after the onset of ischemia to establish a therapeutic time window for neuroprotection. Outcome measurements included both histological and behavioral. Mitochondrial function and matrix metalloproteinase activity in controls and treated rats were also determined. Results— The pharmacokinetic studies showed that AA (75 mg/kg) has a half-life of 2.0 hours. AA significantly decreased infarct volume and improved neurological outcome even when administration was at time points up to 12 hours after the onset of ischemia. Infarct volume was also significantly decreased in female rats and spontaneously hypertensive rats. AA attenuated mitochondrial dysfunction and reduced matrix metalloproteinase-9 induction. Conclusions— Our study shows AA is effective against multiple models of focal ischemia, has a long therapeutic time window, and is also effective in females and hypertensive animals. AA may mediate neuroprotection by protecting mitochondria and inhibiting matrix metalloproteinase-9 induction and activation. Taken together these data suggest that AA is an excellent candidate for development as a stroke therapy.This publication has 28 references indexed in Scilit:
- Focal cerebral ischemia and mitochondrial dysfunction in the TNFα-transgenic ratBrain Research, 2011
- Update of the Stroke Therapy Academic Industry Roundtable Preclinical RecommendationsStroke, 2009
- Asiatic acid, a pentacyclic triterpene from Centella asiatica, is neuroprotective in a mouse model of focal cerebral ischemiaJournal of Neuroscience Research, 2009
- Current Status of Neuroprotection for Cerebral IschemiaStroke, 2009
- Neuroprotective effect of 20(S)-ginsenoside Rg3 on cerebral ischemia in ratsNeuroscience Letters, 2005
- Asiatic acid derivatives enhance cognitive performance partly by improving acetylcholine synthesisJournal of Pharmacy and Pharmacology, 2004
- Matrix Metalloproteinase Expression Is Related to Hemorrhagic Transformation After Cardioembolic StrokeStroke, 2001
- Ischemic Preconditioning Preserves Mitochondrial Function after Global Cerebral Ischemia in Rat HippocampusJournal of Cerebral Blood Flow & Metabolism, 2001
- Protective effects of asiaticoside derivatives against beta-amyloid neurotoxicityJournal of Neuroscience Research, 1999
- Ischemic Delayed Neuronal DeathStroke, 1995